Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 3/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 13/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13268027 | 0.92 | BRD4 (0.58) | WEE1ALKBRD4JAK2FLT3 | |
| SCHEMBL12854448 | 0.86 | PDGFRA (0.55) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL13268039 | 0.86 | PDGFRA (0.60) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL13268121 | 0.86 | PDGFRA (0.55) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL12854449 | 0.85 | PDGFRB (0.52) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL13268185 | 0.83 | PDGFRA (0.60) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL13268177 | 0.82 | JAK1 (0.57) | WEE1BRD4JAK2FLT3 | |
| SCHEMBL13268016 | 0.82 | BRD4 (0.51) | ALKPDGFRBPDGFRACDK2BRD4 | |
| SCHEMBL3109692 | 0.81 | PDGFRA (0.53) | WEE1ALKPDGFRBPDGFRACCNA2 | |
| SCHEMBL13268232 | 0.78 | BRD4 (0.62) | WEE1ALKBRD4JAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | WEE1 342/4885ALK 3241/4885PDGFRB 1086/4885 |
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | WEE1 236/4885ALK 3686/4885PDGFRB 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.